Vor Biopharma Inc. (VOR)

NASDAQ: VOR · Real-Time Price · USD
0.934
-0.024 (-2.48%)
At close: Sep 18, 2024, 4:00 PM
0.920
-0.014 (-1.52%)
Pre-market: Sep 19, 2024, 4:15 AM EDT
-2.48%
Market Cap 63.90M
Revenue (ttm) n/a
Net Income (ttm) -118.09M
Shares Out 68.40M
EPS (ttm) -1.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 671,545
Open 0.970
Previous Close 0.958
Day's Range 0.906 - 0.990
52-Week Range 0.700 - 3.140
Beta -0.34
Analysts Strong Buy
Price Target 10.92 (+1,068.92%)
Earnings Date Nov 5, 2024

About VOR

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinic... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 168
Stock Exchange NASDAQ
Ticker Symbol VOR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for VOR stock is "Strong Buy." The 12-month stock price forecast is $10.92, which is an increase of 1,068.92% from the latest price.

Price Target
$10.92
(1,068.92% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

Thursday, Vor Biopharma Inc. VOR announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel followed by My...

12 days ago - Benzinga

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 st...

13 days ago - GlobeNewsWire

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming inve...

21 days ago - GlobeNewsWire

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June ...

5 weeks ago - GlobeNewsWire

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 31, 2024, the Compensation C...

6 weeks ago - GlobeNewsWire

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March ...

4 months ago - GlobeNewsWire

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of ...

4 months ago - GlobeNewsWire

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

CAMBRIDGE, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full y...

6 months ago - GlobeNewsWire

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

CAMBRIDGE, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host vi...

8 months ago - GlobeNewsWire

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

CAMBRIDGE, Mass., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, announced today it has dosed the first patient in VBP301, its Phase 1/2...

8 months ago - GlobeNewsWire

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host vi...

10 months ago - GlobeNewsWire

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in VBP101, ...

11 months ago - GlobeNewsWire

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended Septe...

11 months ago - GlobeNewsWire

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that preclinical and clinical data supporting the Compa...

11 months ago - GlobeNewsWire

Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update

CAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June ...

1 year ago - GlobeNewsWire

Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will host in-person 1x1 investor meetings at the 2023 Wedbush PacGrow H...

1 year ago - GlobeNewsWire

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: CBUSLUCY
1 year ago - Benzinga

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform

CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in VBP101, ...

1 year ago - GlobeNewsWire

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will present and host in-person 1x1 investor meetings at the Goldman Sa...

1 year ago - GlobeNewsWire

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March ...

1 year ago - GlobeNewsWire

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells

Vor Biopharma Inc. is the brainchild of Dr. Siddhartha Mukherjee. Its core idea is to make CAR-Ts safer by using stem cells.

1 year ago - Seeking Alpha

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

CAMBRIDGE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full y...

1 year ago - GlobeNewsWire

First AML Patient Transplanted with Vor Bio's Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, presented clinical data from VBP101, its Phase 1/2a multicenter, open-l...

1 year ago - GlobeNewsWire

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in VB...

1 year ago - GlobeNewsWire

Vor Bio to Present at B. Riley Securities' 3rd Annual Oncology Conference

CAMBRIDGE, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley Se...

1 year ago - GlobeNewsWire